Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Comment by TiffinTechon Mar 20, 2020 4:00pm

454 Views

Post# 30831826

RE:20 Vaccines in Development

To my understanding Vaxil Bio, should be acquiring their Covid-19 vaccine in April at some point. My boyfriend is friends with the owner of DAVPART, & helps out in business. Their office happens to be stationed where Vaxil's Toronto office is as well *hint hint :-)

Compare the address with Vaxil Bio's if you skeptical. Have a good weekend everyone!!

DAVPART

reeJoey wrote: And I know one of them--all factors considered, I like our odds.

https://www.cnbc.com/2020/03/20/who-officials-say-at-least-20-coronavirus-vaccines-are-in-development-in-global-race-for-cure.html

[/quote]

Bullboard Posts

Mining companies take action on reconciliation with First Nations